- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | BiomX Inc. - 8-K, Current Report | - | SEC Filings | ||
| 29.12.25 | BiomX Inc. - 8-K, Current Report | 7 | SEC Filings | ||
| BIOMX Aktie jetzt für 0€ handeln | |||||
| 29.12.25 | BiomX Inc: BiomX Announces $3.0 Million Private Placement | 3 | GlobeNewswire (USA) | ||
| 17.12.25 | BiomX collapses into court proceedings after clinical trial fails | 6 | CTech | ||
| 08.12.25 | BiomX Inc: BiomX Announces Discontinuation of Phase 2b BX004 Trial Following Internal Review | 158 | GlobeNewswire (Europe) | Following internal analysis and Data Monitoring Committee (DMC) feedback, the Company has elected to discontinue the BX004 Cystic Fibrosis (CF) Phase 2b trial BiomX continues to see potential in... ► Artikel lesen | |
| 08.12.25 | BiomX Inc. - 8-K, Current Report | - | SEC Filings | ||
| 28.11.25 | H.C. Wainwright reiterates Buy rating on BiomX stock amid FDA queries | 10 | Investing.com | ||
| 28.11.25 | BiomX: H.C. Wainwright bestätigt Kaufempfehlung trotz FDA-Rückfragen zum Inhalator | 5 | Investing.com Deutsch | ||
| 26.11.25 | BiomX Awaits FDA Clearance To Restart Cystic Fibrosis Trial After Nebulizer Device Review | 8 | Benzinga.com | ||
| 26.11.25 | BiomX To Continue Cystic Fibrosis Study With Revised Dosing Of BX004; Data Expected In Q2, 2026 | 1 | RTTNews | ||
| 25.11.25 | BiomX Inc: BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis | 203 | GlobeNewswire (Europe) | The Company continues working with the third-party manufacturer to address recent FDA follow-up information requests which are required to lift the clinical hold concerning the nebulizer device used... ► Artikel lesen | |
| 25.11.25 | BiomX Inc. - 8-K, Current Report | - | SEC Filings | ||
| 14.11.25 | BiomX announces 1-for-19 reverse stock split | 4 | Seeking Alpha | ||
| 14.11.25 | BiomX to implement 1-for-19 reverse stock split on November 25 | 1 | Investing.com | ||
| 14.11.25 | BiomX Inc. Announces 1-for-19 Reverse Stock Split | 175 | GlobeNewswire (Europe) | NESS ZIONA, Israel, Nov. 14, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting... ► Artikel lesen | |
| 12.11.25 | BiomX outlines imminent FDA feedback and targets BX004 Phase IIb data in Q1 2026 while advancing BX011 for diabetic foot infections | 2 | Seeking Alpha | ||
| 12.11.25 | BiomX GAAP EPS of $0.29 | 2 | Seeking Alpha | ||
| 12.11.25 | BiomX Inc: BiomX Reports Third Quarter 2025 Financial Results and Provides Program Updates | 341 | GlobeNewswire (Europe) | Positive FDA feedback confirms clear clinical pathway for BX011 targeting S. aureus in Diabetic Foot Infections, building on Company's prior Phase 2 success BiomX expects FDA feedback on BX004 clinical... ► Artikel lesen | |
| 12.11.25 | BiomX Inc. - 8-K, Current Report | - | SEC Filings | ||
| 11.11.25 | Earnings Preview For BiomX | 2 | Benzinga.com |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 85,70 | +2,08 % | BYD gegen Tesla! KI-Profiteure BioNTech und Rio Tinto Partner Aspermont! Aktien für 2026? | Paukenschlag kurz vor Silvester! BYD hat Tesla vom E-Auto-Thron gestoßen. Die Chinesen sind jetzt auch Weltmarktführer bei rein elektrischen Fahrzeugen. Doch die Aktie hat 2025 klar enttäuscht. Ein... ► Artikel lesen | |
| AMGEN | 293,00 | +3,74 % | Amgen übernimmt Dark Blue für bis zu 840 Millionen Dollar | DJ Amgen übernimmt Dark Blue für bis zu 840 Millionen Dollar
Von Colin Kellaher
DOW JONES--Amgen hat das britische Biotechnologieunternehmen Dark Blue Therapeutics für bis zu 840 Millionen... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,450 | +5,84 % | INOVIO Pharmaceuticals, Inc.: FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP) | PLYMOUTH MEETING, Pa., Dec. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,431 | -0,23 % | Defence Therapeutics Inc.: Defence Therapeutics Announces AGM Results and Provides Corporate Updates | Montreal, Quebec--(Newsfile Corp. - December 10, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a biotechnology company advancing a proprietary... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,836 | +2,93 % | PacBio Announces Third Quarter 2025 Financial Results | MENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2025. Third quarter results: Q3 2025Q3 2024Revenue$38.4... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 0,847 | -1,51 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
17.12.2025 / 14:38 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| REDHILL BIOPHARMA | 1,220 | -12,23 % | What's Going On With Redhill Biopharma Stock On Tuesday? | ||
| FIBROGEN | 7,550 | -3,82 % | FibroGen, Inc.: FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum | Name change to Kyntra Bio reflects the newly sharpened focus of the Company on novel therapies with potential for outsized impact in oncology and rare diseaseKyntra Bio will begin trading on Nasdaq... ► Artikel lesen | |
| LEXAGENE | - | - | SOLARIA ENERGIA Y MEDIOAMBIENTE, S.A.: Solaria reports it has signed an agreement with Stoneshield Capital to create a new joint venture, Gravyx, specialising in standalone batteries. | ||
| ARMATA PHARMACEUTICALS | 5,050 | -0,98 % | Jones Trading startet Coverage für Armata Pharmaceuticals mit Kaufempfehlung und hohem Kursziel | ||
| VAXCYTE | 39,400 | +2,60 % | Evercore ISI reiterates Outperform rating on Vaxcyte stock amid CDC changes | ||
| VERRICA PHARMACEUTICALS | 7,350 | +5,76 % | Verrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH (VP-102) for the Treatment of Common Warts | - Common warts affects approximately 22 million patients in the United States alone, and there are no FDA approved prescription therapies for what is believed to be a multibillion-dollar market opportunity-... ► Artikel lesen | |
| HOOKIPA PHARMA | 0,870 | +3,55 % | HOOKIPA Pharma Inc.: HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead | NEW YORK and VIENNA, Oct. 31, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (OTCID: HOOK, "HOOKIPA") today announced the completion of the sale of its assets related to HOOKIPA's HB-400 program and... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 5,300 | +0,95 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome | First patient dosed in REVEAL pivotal trial evaluating TSHA-102 (N=15, aged 6 to Reached written alignment with FDA on inclusion of =3 months of safety data from ASPIRE trial evaluating TSHA-102... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 23,280 | 0,00 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects | In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases, demonstrated... ► Artikel lesen |
BIOMX INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -0,92 % bei einem Aktienkurs von 2,160 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOMX INC finden Sie auf Wallstreet Online.